Prostate cancer chemoprevention by silibinin: Bench to bedside

Molecular Carcinogenesis

Volumn 45, Issue 6, 2006, Pages 436-442

  Singh, Rana P ^a   Agarwal, Rajesh ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Apoptosis; Cell signaling; Cell cycle regulation

Indexed keywords

CETUXIMAB; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLAVONOID; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PHOSPHATIDYLCHOLINE; SILIBININ; SILYBIN PHYTOSOME; SILYMARIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; AUTOCRINE EFFECT; CANCER INCIDENCE; CANCER MODEL; CELL CYCLE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; HEADACHE; HUMAN; LIVER TOXICITY; METASTASIS; NAUSEA; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PRURITUS; SIGNAL TRANSDUCTION; SILYBUM MARIANUM; TUMOR XENOGRAFT;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SILYMARIN;

MUS MUSCULUS;

EID: 33745002041     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20223     Document Type: Conference Paper

References (20)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
3. Kelloff GJ, Lieberman R, Steele VE, et al. Chemoprevention of prostate cancer: Concepts and strategies. Eur Urol 1999;35:342-250.
4. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-1059.
5. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004;4:1-11.
6. Lage A, Crombet T, Gonzalez G. Targeting epidermal growth factor receptor signaling: Early results and future trends in oncology. Ann Med 2003;35:327-336.
7. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
8. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002;21:1759-1767.
9. Wellington K, Jarwis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-489.
10. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002;4:655-663.
11. Zi X, Agarwai R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-7495.
12. Zi X, Zhang J, Agarwai R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000;60:5617-5620.
13. Zi X, Grasso AW, Kung H, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998;58:1920-1929.
14. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284.
15. Qi L, Singh RP, Lu Y, et al. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther 2003;2:526-531.
16. Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin, Biochem Biophys Res Commun 1999;263:528-536.
17. Sharma Y, Agarwal C, Singh AK, Agarwal R. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 2001;30:224-236.
18. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DCF, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice, and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002;62:3063-3069.
19. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: A comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2005 Oct 3; [Epub ahead of print].
20. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003;22:8271-8282.